Small Intestine Cancer Clinical Trials
Small intestine cancer clinical trials offer participants access to a wide variety of exciting new treatment options, such as innovative surgical techniques, novel radiation therapy delivery methods and more targeted chemotherapy drugs. The main purpose of these studies is to evaluate the effectiveness of a brand-new treatment as compared to the current standard of care. If the results of a clinical trial establish that a new treatment is more effective than the currently available treatments, or equally effective with fewer side effects, the new treatment may become the new standard of care. Every treatment goes through a similar process prior to being made widely available for use in all clinical settings.
Moffitt Cancer Center has a robust portfolio of small intestine cancer clinical trials. At any given time, one or more new therapies are under study, such as:
- Biological therapy – Substances created by the body or in a laboratory are used to enhance, target or restore the body’s immune system to provide a natural defense against cancer.
- Radiation therapy with radiosensitizers – Certain drugs, which have been found to make cancer cells more receptive to radiation therapy, are administered in conjunction with radiation therapy to potentially destroy more cancer.
- Chemotherapy – Drugs injected into a vein or taken by mouth can destroy cancer cells or prevent them from growing, and researchers are continually testing new medications and drug combinations to improve effectiveness and reduce side effects.
- Surgical approaches – Surgery, which is the most commonly recommended form of treatment for small intestine cancer, may be more effective when performed with certain techniques to help remove (resect) an affected portion of the small intestine or create a path for food to bypass a cancerous obstruction.
As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt has established an outstanding reputation for excellence in cancer research. As we continue to expand the knowledge base about all forms of cancer, we use clinical trials as a way to translate breakthrough laboratory discoveries into accessible treatment options for current and future cancer patients, improving their survival rate and quality of life.
If you've been diagnosed with small intestine cancer and are interested in clinical trials, our clinical trial navigators can answer your questions. Call call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 21664
Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).
Condition: Gastrointestinal Tumor
Intervention: Amino acids (); Granisetron (); Lanreotide (); Ondansetron (); RYZ101 (); Sunitinib (); Zofran (Ondansetron); everolimus (RAD001); octreotide LAR ()
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib)
CLINICAL TRIAL 23064
Phase 1 Single Center Study to Evaluate Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Single Agent Mitomycin C (MMC) in Peritoneal Carcinomatosis (PC) from Solid Gastrointestinal Malignancies (sGI-PC) in Palliative Setting
Condition: Gastrointestinal Tumor
Intervention: Fluorouracil (); leucovorin (); mitomycin c ()
CLINICAL TRIAL 23375
Phase II Study of NALIRIFOX (Nanoliposomal Irinotecan + Oxaliplatin with Fluorouracil and Folinic Acid) in Advanced Unresectable Small Bowel Tumors
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Nanoliposomal Irinotecan (); Oxaliplatin (); eloxatin (Oxaliplatin); leucovorin ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()
CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
CLINICAL TRIAL 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()
CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()
CLINICAL TRIAL 24071
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Condition: Multiple
Intervention: Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); RMC-5127 (); RMC-6236 (Daraxonrasib)
CLINICAL TRIAL 24095
Phase 1/2a Open-Label Clinical Trial Evaluating VBC101, an EGFR and cMET Targeted Bi-Specific Antibody Drug Conjugate, in Participants With Advanced Solid Tumor Malignancies
Condition: Multiple
Intervention: VBC101 ()
CLINICAL TRIAL 24103
A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Condition: Multiple
Intervention: KST-6051 ()
CLINICAL TRIAL 24154
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination with Imatinib in Participants with Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Condition: Sarcoma
Intervention: Imatinib (); KQB198 ()
CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24291
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants with Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
Condition: Multiple
Intervention: BLU-924 ()
CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()
CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()